Envestnet Asset Management’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Envestnet Asset Management’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-9,294	Closed	-$997K	–	4128
2023 Q1	$997K	Buy	9,294 +312	+3%	+$35.9K	﹤0.01%	2680
2022 Q4	$988K	Buy	8,982 +3,175	+55%	+$206K	﹤0.01%	2653
2022 Q3	$343K	Buy	+5,807	New	+$266K	﹤0.01%	3255

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Envestnet Asset Management's RXDX Position: Q2 2023 in Review

Envestnet Asset Management sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 9,294 shares — an estimated $997K sold.

Envestnet Asset Management first reported a position in RXDX in Q3 2022 and held it in 3 quarters. The position peaked at $997K in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Envestnet Asset Management reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Envestnet Asset Management sold 9,294 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $997K.
Envestnet Asset Management first reported a position in Prometheus Biosciences, Inc. Common Stock in Q3 2022 and held it in 3 quarters.
Envestnet Asset Management's Prometheus Biosciences, Inc. Common Stock position peaked at $997K in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Envestnet Asset Management's 13F filing for Q2 2023, filed 4 Aug 2023.